Global Pcr Based Infectious Diseases Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2024 –2031 |
 Размер рынка (базовый год) |
USD 4,737,570.00 Thousand |
 Размер рынка (прогнозируемый год) |
USD 7,720,895.13 Thousand |
 CAGR |
% |
| Основные игроки рынка |
Глобальный рынок инфекционных заболеваний на основе ПЦР, по типу теста (тест ПЦР на туберкулез, тест ПЦР на гепатит, тест ПЦР на вирус иммунодефицита человека (ВИЧ), тест ПЦР на грипп, тест ПЦР на вирус папилломы человека (ВПЧ), тест ПЦР на гонорею, тест ПЦР на сальмонеллез, тест ПЦР на ротавирус, тест ПЦР на бордетеллы, тест ПЦР на H. Pylori, тест ПЦР на норовирус, тест ПЦР на SARS (COVID-19), тест ПЦР на энтерококки, тест ПЦР на генитальный хламидии трахоматис, тест ПЦР на C. Difficile (Clostridium Difficile), тест ПЦР на энтеробактерии, устойчивые к карбапенемам (CRE), тест ПЦР на микоплазму гениталиум (MG), тест ПЦР на метициллин-устойчивый золотистый стафилококк (MRSA) и другие), инфекция (вирусная инфекция, инфекция дыхательных путей, инфекция, передающаяся половым путем, внутрибольничные инфекции и другие инфекции), патоген (вирусный, бактериальный, грибковый, простейший и другие), технология ПЦР (ОТ-ПЦР, мультиплексная ПЦР и другие), тип пациента (гериатрический, детский и взрослый), тестирование (лабораторное тестирование и тестирование по месту оказания медицинской помощи), конечный пользователь (диагностические центры, больницы, академические и научно-исследовательские институты, общественные медицинские центры, клиники, уход на дому и другие) — тенденции отрасли и прогноз до 2031 года.
Анализ и размер рынка инфекционных заболеваний на основе ПЦР
Глобальный рынок инфекционных заболеваний на основе ПЦР обусловлен ростом заболеваемости инфекционными заболеваниями во всем мире, включая респираторные инфекции, инфекции, передающиеся половым путем , желудочно-кишечные инфекции и трансмиссивные заболевания, что является важным фактором роста рынка. Более того, рост спроса на быстрые и точные методы диагностики еще больше стимулирует рост рынка. Однако нехватка надежного электричества, обученного персонала и лабораторных помещений может помешать широкому внедрению тестов на основе ПЦР, что сдерживает рост рынка.
По данным исследования рынка Data Bridge, ожидается, что объем мирового рынка инфекционных заболеваний на основе ПЦР достигнет 7 720 895,13 тыс. долларов США к 2031 году по сравнению с 4 737 570,00 тыс. долларов США в 2023 году, а среднегодовой темп роста составит 6,6% в прогнозируемый период с 2024 по 2031 год.
|
Отчет Метрика |
Подробности |
|
Прогнозируемый период |
2024-2031 |
|
Базовый год |
2023 |
|
Исторические годы |
2022 (настраиваемый 2016-2021) |
|
Количественные единицы |
Доход в тыс. долл. США, объем в единицах, средняя цена продажи в долл. США |
|
Охваченные сегменты |
Тип теста (ПЦР-тест на туберкулез, ПЦР-тест на гепатит, ПЦР-тест на вирус иммунодефицита человека (ВИЧ), ПЦР-тест на грипп, ПЦР-тест на вирус папилломы человека (ВПЧ), ПЦР-тест на гонорею, ПЦР-тест на сальмонеллез, ПЦР-тест на ротавирус, ПЦР-тест на бордетеллы, ПЦР-тест на H. Pylori, ПЦР-тест на норовирус, ПЦР-тест на SARS (COVID-19), ПЦР-тест на энтерококки, ПЦР-тест на генитальные инфекции Chlamydia Trachomatis, ПЦР-тест на C. Difficile (Clostridium Difficile), ПЦР-тест на энтеробактерии, устойчивые к карбапенемам (CRE), ПЦР-тест на микоплазму гениталиум (MG), ПЦР-тест на метициллин-устойчивый золотистый стафилококк (MRSA) и другие ПЦР-тесты), инфекция (вирусная инфекция, инфекция дыхательных путей, Инфекции, передающиеся половым путем, внутрибольничные инфекции и другие инфекции), патоген (вирусный, бактериальный, грибковый, простейший и другие), технология ПЦР (ОТ-ПЦР, мультиплексная ПЦР и другие), тип пациента (гериатрический, детский и взрослый), тестирование (лабораторное тестирование и тестирование по месту оказания медицинской помощи), конечный пользователь (диагностические центры, больницы, академические и научно-исследовательские институты, общественные медицинские центры, клиники, домашняя медицинская помощь и другие) |
|
Страны, охваченные |
США, Канада, Мексика, Германия, Великобритания, Италия, Франция, Испания, Россия, Швейцария, Турция, Бельгия, Нидерланды, Венгрия, остальные страны Европы, Япония, Китай, Южная Корея, Индия, Сингапур, Таиланд, Индонезия, Малайзия, Филиппины, Австралия, остальные страны Азиатско-Тихоокеанского региона, Бразилия, Аргентина, остальные страны Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ, Израиль и остальные страны Ближнего Востока и Африки |
|
Охваченные участники рынка |
DNA Labs India, DrSafeHands, Ganesh Diagnostic & Imaging Centre Pvt. Ltd., Max Lab, MicroGen Diagnostics, pathlab, The Washington Travel Clinic, Clarewell Clinics, AZOVA, One Life Home Health Care Center и LalPathLabs среди других |
Определение рынка
Глобальный рынок инфекционных заболеваний на основе ПЦР охватывает динамическую экосистему продуктов и услуг, направленных на обнаружение и управление инфекционными патогенами с помощью применения технологии полимеразной цепной реакции (ПЦР). Этот рынок включает в себя разнообразный спектр ПЦР-анализов, инструментов, реагентов и программных решений, предназначенных для идентификации и характеристики различных инфекционных агентов, включая вирусы, бактерии, грибки и паразитов. ПЦР-анализы и наборы разрабатываются для конкретных патогенов, охватывая широкий спектр инфекционных заболеваний, таких как респираторные инфекции, заболевания, передающиеся половым путем, желудочно-кишечные заболевания и возникающие инфекционные угрозы. ПЦР-инструменты, включая термоциклеры и системы ПЦР в реальном времени, облегчают амплификацию и обнаружение целевых нуклеиновых кислот в клинических образцах, в то время как реагенты и расходные материалы поддерживают лабораторный рабочий процесс с помощью основных компонентов для реакций ПЦР. Более того, программное обеспечение и биоинформатические инструменты помогают в анализе данных, интерпретации и представлении результатов ПЦР-анализа, повышая точность и эффективность диагностики.
Динамика мирового рынка инфекционных заболеваний на основе ПЦР
В этом разделе рассматривается понимание движущих сил рынка, преимуществ, возможностей, ограничений и проблем. Все это подробно обсуждается ниже:
Драйверы
- Расширение исследований на основе ПЦР
ПЦР стала ключевым методом в области диагностики и исследования инфекционных заболеваний из-за ее непревзойденной чувствительности, специфичности и эффективности в обнаружении и амплификации нуклеиновых кислот. Постоянный прогресс в технологиях ПЦР в сочетании с более глубоким пониманием генетического состава патогенов позволил создать высокоточные и целесообразные диагностические анализы. Постоянные усовершенствования технологии ПЦР, такие как цифровая и ПЦР в реальном времени, повысили эффективность и скорость диагностики инфекционных заболеваний. Эти разработки позволяют быстрее и точнее идентифицировать патогены, что позволяет оперативно вмешиваться и лечить. Росту тестирования в местах оказания медицинской помощи, которое увеличивает доступ к диагностике в различных медицинских учреждениях, также способствует постоянное совершенствование методов ПЦР.
- Рост числа случаев инфекционных заболеваний
Рост глобализации, урбанизация и ухудшение состояния окружающей среды являются одними из причин, обуславливающих рост частоты инфекций во всем мире, что сделало надежные диагностические, терапевтические и профилактические методы лечения критически необходимыми. Общественное здравоохранение по-прежнему серьезно подвержено угрозе со стороны инфекционных заболеваний , которые усложняются новыми развивающимися патогенами и повторным появлением болезней, которые ранее находились под контролем.
Возможности
- Эпиднадзор для раннего выявления и мониторинга инфекционных заболеваний
Способность тестов на основе ПЦР предлагать надежный инструмент для непрерывного наблюдения за заболеваниями представляет собой значительную возможность для роста рынка. Эти тесты, характеризующиеся высокой чувствительностью и специфичностью, позволяют осуществлять раннее обнаружение и непрерывный мониторинг инфекционных заболеваний среди населения. Характер ПЦР в режиме реального времени позволяет своевременно идентифицировать патогены, облегчая меры быстрого реагирования и эффективные стратегии сдерживания.
Этот проактивный подход имеет решающее значение для предотвращения распространения инфекционных заболеваний и смягчения их воздействия на общественное здравоохранение. В результате, возможность заключается в способности рынка вносить вклад в глобальное здравоохранение, предоставляя передовые инструменты для наблюдения за заболеваниями, позволяя проводить раннее вмешательство и в конечном итоге улучшая результаты здравоохранения.
- Рост инноваций в технологии ПЦР
Текущие инновации в технологии ПЦР, в частности, достижения в ПЦР в реальном времени и мультиплексных ПЦР-анализах, представляют собой существенную возможность для роста рынка. Эти технологические прорывы значительно расширяют возможности тестирования, предлагая более эффективные, экономичные и комплексные диагностические решения. ПЦР в реальном времени позволяет проводить одновременную амплификацию и количественную оценку нуклеиновых кислот, обеспечивая быстрые и точные результаты. Между тем, мультиплексные ПЦР-анализы позволяют обнаруживать несколько целей в одной реакции, способствуя более тщательному анализу инфекционных агентов. Эти достижения не только повышают скорость и точность диагностики, но и повышают экономическую эффективность за счет объединения нескольких тестов в один процесс.
Ограничения/Проблемы
- Высокая стоимость услуг ПЦР-тестирования
ПЦР — это мощный и точный диагностический метод, который обеспечивает точную идентификацию патогена. Однако высокая стоимость ПЦР-тестирования отчасти обусловлена передовыми технологиями и необходимостью использования определенных инструментов, материалов и квалифицированного персонала. Доступность может быть ограничена стоимостью внедрения и обслуживания диагностики на основе ПЦР, особенно в регионах с ограниченными ресурсами и ограниченными бюджетами здравоохранения. Диагностика и сдерживание инфекционных заболеваний могут быть отложены из-за высокой стоимости ПЦР-тестов, что может препятствовать проведению крупномасштабных операций по тестированию.
Есть и другие причины, которые увеличивают стоимость ПЦР-тестирования. Во-первых, использование самой технологии требует дорогостоящих специализированных реагентов и сложного оборудования. Первоначальные инвестиции, необходимые лабораториям для создания возможностей ПЦР, увеличиваются из-за необходимости в точных приборах, таких как термоциклеры и машины для извлечения нуклеиновых кислот.
- Проблемы безопасности и конфиденциальности данных
Растущая зависимость от цифровых платформ для отчетности и анализа результатов ПЦР-тестов порождает проблему для роста рынка — проблемы безопасности данных и конфиденциальности. Обеспечение конфиденциальности и безопасной обработки конфиденциальных медицинских данных становится первостепенной задачей, поскольку интеграция цифровых технологий становится все более распространенной в процессе тестирования. Потенциальные уязвимости в безопасности данных вызывают опасения по поводу несанкционированного доступа, нарушений и неправомерного использования личной медицинской информации. Решение этих проблем имеет решающее значение не только для соблюдения строгих правил защиты данных, но и для поддержания общественного доверия к процессу тестирования. Нарушение безопасности данных может подорвать уверенность в точности и надежности ПЦР-тестирования на инфекционные заболевания, что повлияет как на отдельных лиц, так и на более широкие инициативы общественного здравоохранения. Поэтому, поскольку рынок продолжает развиваться и внедрять цифровизацию, он должен отдавать приоритет надежным мерам защиты данных и прозрачным протоколам конфиденциальности, чтобы смягчить эти проблемы и сохранить доверие общественности, которой он служит.
Последние события
- В сентябре 2023 года Pathlab запустила программу первичного скрининга вируса папилломы человека (ВПЧ). Тест на ВПЧ можно проводить с использованием существующего образца жидкостной цитологии (ЖЦ) (SurePath) или с использованием самостоятельно собранного или собранного врачом вагинального мазка. Эта программа расширила диагностические возможности, предложив гибкость в проведении тестов на ВПЧ
- В августе 2022 года MicroGen Diagnostics расширила свою деятельность в области обнаружения ортопедических и урологических инфекций на основе целевого секвенирования после получения новых контрактов и начала исследований результатов. Этот стратегический шаг не только расширил спектр услуг компании, но и открыл возможности для увеличения доходов за счет новых контрактов
- В июне 2021 года MicroGen Diagnostics расширила свои возможности и компетенции в области неклинических первичных исследований за счет приобретения партнерской лаборатории RTL Genomics. Этот стратегический шаг позволил компании расширить сферу своей исследовательской деятельности, исследовать новые направления научных исследований и потенциально привести к новаторским открытиям.
Масштаб мирового рынка инфекционных заболеваний на основе ПЦР
Глобальный рынок инфекционных заболеваний на основе ПЦР сегментирован на семь заметных сегментов на основе типа теста, инфекции, патогена, технологии ПЦР, типа пациента, тестирования и конечного пользователя. Рост среди этих сегментов поможет вам проанализировать основные сегменты роста в отраслях и предоставить пользователям ценный обзор рынка и рыночные идеи, которые помогут им принимать стратегические решения для определения основных рыночных приложений.
Тип теста
- ПЦР-тест на туберкулез
- ПЦР-тест на гепатит
- ПЦР-тест на вирус иммунодефицита человека (ВИЧ)
- ПЦР-тест на грипп
- ПЦР-тест на вирус папилломы человека (ВПЧ)
- Тест на гонорею ПКТ
- ПЦР-тест на сальмонеллез
- ПЦР-тест на ротавирус
- ПЦР-тест на Бордетеллы
- ПЦР-тест на H. Pylori
- ПЦР-тест на норовирус
- ПЦР-тест на SARS (COVID-19)
- ПЦР-тест на энтерококки
- ПЦР-тест на генитальный Chlamydia Trachomatis
- ПЦР-тест на C.difficile (Clostridium Difficile)
- ПЦР-тест на наличие энтеробактерий, устойчивых к карбапенемам (CRE)
- ПЦР-тест на Mycoplasma Genitalium (MG)
- ПЦР-тест на метициллин-резистентный золотистый стафилококк (MRSA)
- Другой ПЦР-тест
На основе типа теста рынок сегментирован на ПЦР-тест на туберкулез, ПЦР-тест на гепатит, ПЦР-тест на вирус иммунодефицита человека (ВИЧ), ПЦР-тест на грипп, ПЦР-тест на вирус папилломы человека (ВПЧ), ПЦР-тест на гонорею, ПЦР-тест на сальмонеллез, ПЦР-тест на ротавирус, ПЦР-тест на бордетеллы, ПЦР-тест на H. Pylori, ПЦР-тест на норовирус, ПЦР-тест на SARS (COVID-19), ПЦР-тест на энтерококк, ПЦР-тест на генитальный хламидию трахоматис, ПЦР-тест на C. Difficile (Clostridium Difficile), ПЦР-тест на энтеробактерии, устойчивые к карбапенемам (Cre), ПЦР-тест на Mycoplasma Genitalium (Mg), ПЦР-тест на метициллин-устойчивый золотистый стафилококк (Mrsa) и другие ПЦР-тесты.
Инфекция
- Вирусная инфекция
- Инфекция дыхательных путей
- Инфекции, передающиеся половым путем
- Внутрибольничные инфекции
- Другие инфекции
По типу инфекции рынок сегментируется на вирусные инфекции, инфекции дыхательных путей, инфекции, передающиеся половым путем, внутрибольничные инфекции и прочие инфекции.
Возбудитель
- Популярный
- Бактериальный
- Грибковый
- Простейшие
- Другие
В зависимости от патогена рынок сегментируется на вирусные, бактериальные, грибковые, простейшие и другие.
Технология ПЦР
- ОТ-ПЦР
- Мультиплексная ПЦР
- Другие
На основе технологии ПЦР рынок сегментируется на ОТ-ПЦР, мультиплексную ПЦР и другие.
Тип пациента
- гериатрический
- Педиатрический
- Взрослые
В зависимости от типа пациентов рынок сегментируется на гериатрический, педиатрический и взрослый.
Тестирование
- Лабораторные испытания
- Тестирование в месте оказания медицинской помощи
На основе тестирования рынок сегментируется на лабораторное тестирование и тестирование в местах оказания медицинской помощи.
Конечный пользователь
- Диагностические центры
- Больница
- Академические и научно-исследовательские институты
- Общественные центры здоровья
- Клиники
- Домашнее здравоохранение
- Другие
По типу конечного пользователя рынок сегментируется на диагностические центры, больницы, академические и научно-исследовательские институты, общественные медицинские центры, клиники, учреждения по оказанию медицинской помощи на дому и другие.
Региональный анализ/информация о мировом рынке инфекционных заболеваний на основе ПЦР
Глобальный рынок диагностики инфекционных заболеваний на основе ПЦР делится на семь основных сегментов в зависимости от типа теста, инфекции, патогена, технологии ПЦР, типа пациента, метода тестирования и конечного пользователя.
В данном отчете о рынке рассматриваются следующие страны: США, Канада, Мексика, Германия, Великобритания, Италия, Франция, Испания, Россия, Швейцария, Турция, Бельгия, Нидерланды, Венгрия, остальные страны Европы, Япония, Китай, Южная Корея, Индия, Сингапур, Таиланд, Индонезия, Малайзия, Филиппины, Австралия, остальные страны Азиатско-Тихоокеанского региона, Бразилия, Аргентина, остальные страны Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ, Израиль, а также остальные страны Ближнего Востока и Африки.
Ожидается, что регион Северной Америки будет доминировать на рынке из-за наличия передовой инфраструктуры здравоохранения, технологических инноваций, особенно в области биотехнологий и молекулярной диагностики, и высокого спроса на диагностику. Ожидается, что США будут доминировать в регионе Северной Америки из-за наличия передовой инфраструктуры здравоохранения, технологических инноваций, особенно в области биотехнологий и молекулярной диагностики, и высокого спроса на диагностику. Ожидается, что Германия будет доминировать в регионе Европы из-за своего сильного присутствия на международных рынках с обширными дистрибьюторскими сетями и каналами продаж, а также значительным акцентом на исследования и разработки в секторе наук о жизни. Ожидается, что Китай будет доминировать в Азиатско-Тихоокеанском регионе из-за его большого населения, высокого бремени болезней, быстрого экономического роста и расширения здравоохранения.
Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости вверх и вниз по течению, технические тенденции, анализ пяти сил Портера и тематические исследования, являются некоторыми из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность глобальных брендов и их проблемы, связанные с большой или малой конкуренцией со стороны местных и глобальных брендов, влияние глобальных тарифов и торговые пути.
Анализ конкурентной среды и доли рынка на мировом рынке инфекционных заболеваний на основе ПЦР
Конкурентная среда мирового рынка инфекционных заболеваний на основе ПЦР содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта и доминировании в применении. Приведенные выше данные касаются только фокуса компаний на рынке.
Среди основных игроков, работающих на мировом рынке диагностики инфекционных заболеваний с использованием метода ПЦР, можно назвать DNA Labs India, DrSafeHands, Ganesh Diagnostic & Imaging Centre Pvt. Ltd., Max Lab, MicroGen Diagnostics, pathlab, The Washington Travel Clinic, Clarewell Clinics, AZOVA, One Life Home Health Care Center, LalPathLabs и другие.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES
5.1.2 RISING CASES OF INFECTIOUS DISEASES
5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS
5.2 RESTRAINTS
5.2.1 HIGH COST OF PCR TEST SERVICES
5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS
5.3 OPPORTUNITIES
5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES
5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY
5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS
5.4 CHALLENGES
5.4.1 DATA SECURITY AND PRIVACY CONCERNS
5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE
6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE
6.1 OVERVIEW
6.2 TUBERCULOSIS PCR TEST
6.3 HEPATITIS PCR TEST
6.3.1 HEPATITIS C PCR TEST
6.3.2 HEPATITIS B PCR TEST
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST
6.5 INFLUENZA PCR TEST
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST
6.8 GONORRHEA PCR TEST
6.9 SALMONELLOSIS PCR TEST
6.1 ROTAVIRUS PCR TEST
6.11 BORDETELLA PCR TEST
6.12 H. PYLORI PCR TEST
6.13 SARS (COVID-19) PCR TEST
6.14 NOROVIRUS PCR TEST
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST
6.17 ENTEROCOCCUS PCR TEST
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST
6.2 OTHERS PCR TEST
7 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION
7.1 OVERVIEW
7.2 VIRAL INFECTION
7.2.1 SARS (COVID-19) INFECTION
7.2.2 ROTAVIRUS INFECTION
7.2.3 NOROVIRUS INFECTION
7.2.4 OTHERS
7.3 RESPIRATORY TRACT INFECTION
7.3.1 INFLUENZA
7.3.2 TUBERCULOSIS
7.3.3 BORDETELLA
7.4 SEXUALLY TRANSMITTED INFECTION
7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION
7.4.2 GONORRHEA
7.4.3 HEAPTITIS
7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
7.4.5 HUMAN PAPILLOMAVIRUS (HPV)
7.4.6 MYCOPLASMA GENITALIUM (MG)
7.4.7 OTHERS
7.5 HOSPITAL ACQUIRED INFECTIONS
7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE)
7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE)
7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
7.5.4 OTHERS
7.6 OTHER INFECTIONS
7.6.1 SALMONELLOSIS
7.6.2 H. PYLORI
7.6.3 ENTEROCOCCUS INFECTIONS
7.6.4 OTHERS
8 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN
8.1 OVERVIEW
8.2 VIRAL
8.3 BACTERIAL
8.4 FUNGAL
8.5 PROTOZOA
8.6 OTHERS
9 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY
9.1 OVERVIEW
9.2 RT PCR
9.3 MULTIPLEX PCR
9.4 OTHERS
10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 GERIATRIC
10.3 PEDIATRIC
10.4 ADULTS
11 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING
11.1 OVERVIEW
11.2 LABORATORY BASED TESTING
11.3 POINT OF CARE TESTING
12 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER
12.1 OVERVIEW
12.2 DIAGNOSTIC CENTERS
12.3 HOSPITAL
12.4 CLINICS
12.5 COMMUNITY HEALTH CENTERS
12.6 ACADEMIC AND RESEARCH INSTITUTES
12.7 HOME HEALTHCARE
12.8 OTHERS
13 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 RUSSIA
13.3.6 SPAIN
13.3.7 TURKEY
13.3.8 NETHERLANDS
13.3.9 SWITZERLAND
13.3.10 BELGIUM
13.3.11 HUNGARY
13.3.12 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 CHINA
13.4.2 AUSTRALIA
13.4.3 JAPAN
13.4.4 INDIA
13.4.5 SOUTH KOREA
13.4.6 SINGAPORE
13.4.7 MALAYISA
13.4.8 THAILAND
13.4.9 INDONESIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 U.A.E.
13.6.3 SAUDI ARABIA
13.6.4 EGYPT
13.6.5 ISRAEL
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MICROGEN DIAGNOSTICS
16.1.1 COMPANY SNAPSHOT
16.1.2 SERVICE PORTFOLIO
16.1.3 RECENT DEVELOPMENTS
16.2 MAX LAB
16.2.1 COMPANY SNAPSHOT
16.2.2 SERVICE PORTFOLIO
16.3 DNA LABS INDIA
16.3.1 COMPANY SNAPSHOT
16.3.2 SERVICE PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 SERVICE PORTFOLIO
16.4.3 RECENT DEVELOPMENT
16.5 LALPATHLABS
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 AZOVA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 CLAREWELL CLINICS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT DESCRIPTION
16.7.3 RECENT DEVELOPMENTS
16.8 DRSAFEHANDS
16.8.1 COMPANY SNAPSHOT
16.8.2 SERVICE PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ONE LIFE HOME HEALTH CARE CENTER
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT DESCRIPTION
16.9.3 RECENT DEVELOPMENTS
16.1 PATHLAB
16.10.1 COMPANY SNAPSHOT
16.10.2 SERVICE PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 THE WASHINGTON TRAVEL CLINIC
16.11.1 COMPANY SNAPSHOT
16.11.2 SERVICE PORTFOLIO
16.11.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Список таблиц
TABLE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 4 GLOBAL TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 8 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 9 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 35 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 38 GLOBAL VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 GLOBAL BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 GLOBAL FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 GLOBAL PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 44 GLOBAL RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 GLOBAL MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 GLOBAL GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 GLOBAL PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 GLOBAL ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 52 GLOBAL LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 GLOBAL POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 54 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 55 GLOBAL DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 GLOBAL HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 GLOBAL CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 58 GLOBAL COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 GLOBAL HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 62 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 66 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 67 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 69 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 70 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 71 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 72 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 73 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 74 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 75 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 76 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 77 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 78 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 80 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 81 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 83 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 84 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 86 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 87 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 90 U.S. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 91 U.S. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 92 U.S. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 93 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 94 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 95 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 97 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 100 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 101 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 102 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 103 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 104 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 105 CANADA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 106 CANADA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 107 CANADA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 108 CANADA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 109 CANADA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 110 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 111 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 112 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 114 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 115 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 117 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 118 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 120 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 121 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 122 MEXICO VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 123 MEXICO RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 124 MEXICO SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 125 MEXICO HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 126 MEXICO OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 127 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 128 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 129 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 131 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 133 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 135 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 136 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 138 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 139 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 140 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 141 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 142 EUROPE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 143 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 144 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 145 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 146 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 147 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 149 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 150 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 152 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 153 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 155 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 156 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 157 GERMANY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 158 GERMANY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 159 GERMANY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 160 GERMANY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 161 GERMANY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 162 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 163 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 164 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 166 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 167 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 169 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 170 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 172 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 173 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 174 FRANCE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 175 FRANCE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 176 FRANCE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 177 FRANCE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 178 FRANCE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 179 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 184 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 186 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 187 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 189 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 190 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 191 U.K. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 192 U.K. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 193 U.K. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 194 U.K. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 195 U.K. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 196 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 197 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 198 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 200 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 201 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 203 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 204 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 206 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 207 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 208 ITALY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 209 ITALY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 210 ITALY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 211 ITALY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 212 ITALY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 213 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 214 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 215 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 216 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 217 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 218 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 220 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 221 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 222 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 223 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 224 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 225 RUSSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 226 RUSSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 227 RUSSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 228 RUSSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 229 RUSSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 230 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 231 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 232 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 234 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 235 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 237 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 238 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 240 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 241 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 242 SPAIN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 243 SPAIN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 244 SPAIN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 245 SPAIN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 246 SPAIN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 247 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 248 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 249 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 251 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 252 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 254 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 255 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 257 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 258 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 266 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 268 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 269 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 270 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 271 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 272 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 274 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 275 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 276 NETHERLANDS VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 277 NETHERLANDS RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 278 NETHERLANDS SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 279 NETHERLANDS HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 280 NETHERLANDS OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 281 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 282 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 283 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 284 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 285 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 286 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 288 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 289 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 291 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 292 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 293 SWITZERLAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 294 SWITZERLAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 295 SWITZERLAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 296 SWITZERLAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 297 SWITZERLAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 298 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 299 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 300 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 302 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 303 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 305 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 306 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 308 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 309 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 310 BELGIUM VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 311 BELGIUM RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 319 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 320 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 322 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 323 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 325 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 326 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 327 HUNGARY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 328 HUNGARY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 329 HUNGARY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 330 HUNGARY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 331 HUNGARY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 332 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 333 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 334 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 336 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 337 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 338 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 339 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 340 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 341 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 342 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 343 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 344 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 346 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 347 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 348 ASIA-PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 349 ASIA-PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 350 ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 351 ASIA-PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 352 ASIA-PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 353 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 354 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 355 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 357 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 358 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 360 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 361 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 362 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 363 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 364 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 365 CHINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 366 CHINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 367 CHINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 368 CHINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 369 CHINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 370 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 371 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 372 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 374 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 375 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 376 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 377 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 378 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 380 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 381 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 382 AUSTRALIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 383 AUSTRALIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 384 AUSTRALIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 385 AUSTRALIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 386 AUSTRALIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 387 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 388 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 389 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 390 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 391 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 392 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 393 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 394 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 395 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 396 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 397 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 398 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 399 JAPAN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 400 JAPAN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 401 JAPAN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 402 JAPAN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 403 JAPAN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 404 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 405 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 406 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 408 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 409 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 410 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 411 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 412 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 413 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 414 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 415 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 416 INDIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 417 INDIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 418 INDIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 419 INDIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 420 INDIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 421 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 422 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 423 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 424 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 425 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 426 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 427 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 428 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 429 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 430 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 431 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 432 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 433 SOUTH KOREA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 434 SOUTH KOREA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 435 SOUTH KOREA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 436 SOUTH KOREA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 437 SOUTH KOREA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 438 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 439 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 440 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 441 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 442 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 443 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 444 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 445 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 446 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 447 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 448 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 449 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 450 SINGAPORE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 451 SINGAPORE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 452 SINGAPORE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 453 SINGAPORE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 454 SINGAPORE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 455 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 456 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 457 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 458 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 459 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 460 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 461 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 462 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 463 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 464 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 465 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 466 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 467 MALAYSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 468 MALAYSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 469 MALAYSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 470 MALAYSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 471 MALAYSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 472 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 473 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 474 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 475 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 476 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 477 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 479 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 480 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 481 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 482 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 483 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 484 THAILAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 485 THAILAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 486 THAILAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 487 THAILAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 488 THAILAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 489 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 490 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 491 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 492 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 493 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 494 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 495 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 496 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 497 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 499 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 500 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 501 INDONESIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 502 INDONESIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 503 INDONESIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 504 INDONESIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 505 INDONESIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 506 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 507 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 508 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 509 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 510 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 511 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 512 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 513 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 514 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 515 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 516 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 517 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 518 PHILIPPINES VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 519 PHILIPPINES RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 520 PHILIPPINES SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 521 PHILIPPINES HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 522 PHILIPPINES OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 523 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 524 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 525 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 526 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 527 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 528 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 529 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 530 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 531 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 532 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 533 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 534 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 535 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 536 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 537 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 538 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 539 SOUTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 540 SOUTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 541 SOUTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 542 SOUTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 543 SOUTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 544 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 545 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 546 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 548 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 549 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 550 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 551 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 552 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 553 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 554 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 555 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 556 BRAZIL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 557 BRAZIL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 558 BRAZIL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 559 BRAZIL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 560 BRAZIL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 561 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 562 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 563 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 564 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 565 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 566 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 567 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 568 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 569 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 570 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 571 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 572 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 573 ARGENTINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 574 ARGENTINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 575 ARGENTINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 576 ARGENTINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 577 ARGENTINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 578 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 579 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 580 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 581 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 582 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 583 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 584 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 585 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 586 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 587 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 588 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 589 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 590 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 591 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 592 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 593 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 594 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 595 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 596 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 597 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 598 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 599 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 600 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 601 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 602 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 603 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 604 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 605 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 606 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 607 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 608 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 609 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 610 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 611 SOUTH AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 612 SOUTH AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 613 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 614 SOUTH AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 615 SOUTH AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 616 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 617 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 618 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 619 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 620 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 621 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 622 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 623 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 624 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 625 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 626 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 627 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 628 U.A.E. VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 629 U.A.E. RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 630 U.A.E. SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 631 U.A.E. HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 632 U.A.E. OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 633 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 634 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 635 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 636 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 637 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 638 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 640 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 641 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 642 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 643 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 644 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 645 SAUDI ARABIA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 646 SAUDI ARABIA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 647 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 648 SAUDI ARABIA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 649 SAUDI ARABIA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 650 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 651 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 652 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 654 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 655 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 656 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 657 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 658 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 660 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 661 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 662 EGYPT VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 663 EGYPT RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 664 EGYPT SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 665 EGYPT HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 666 EGYPT OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 667 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 668 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 669 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 670 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 671 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 672 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 673 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 674 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 675 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 676 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 677 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 678 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 679 ISRAEL VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 680 ISRAEL RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 681 ISRAEL SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 682 ISRAEL HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 683 ISRAEL OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND)
TABLE 684 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND)
TABLE 685 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 686 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 687 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND)
TABLE 688 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 689 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 690 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 691 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP)
Список рисунков
FIGURE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION
FIGURE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PCR-BASED INFECTIOUS DISEASE MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET
FIGURE 16 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023
FIGURE 17 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023
FIGURE 21 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031)
FIGURE 23 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE
FIGURE 24 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023
FIGURE 25 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031)
FIGURE 27 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE
FIGURE 28 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023
FIGURE 29 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031)
FIGURE 31 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE
FIGURE 32 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023
FIGURE 33 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031)
FIGURE 35 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE
FIGURE 36 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023
FIGURE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND)
FIGURE 38 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031)
FIGURE 39 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE
FIGURE 40 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023
FIGURE 41 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 42 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031)
FIGURE 43 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023)
FIGURE 45 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
